title: Is Haemophilus influenzae finished?
authors.affiliation: Department of Paediatrics, Imperial College School of Medicine at St Mary's Hospital, London, UK. r.booy@ic.ac.uk
authors.forename: R
authors.initials: R
authors.lastname: Booy
authors.forename: J S
authors.initials: JS
authors.lastname: Kroll
mesh_terms: D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D016667:Bacterial Capsules; D002511:Cephalosporins / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005798:Genes, Bacterial; D006192:Haemophilus Infections / Q000188:drug therapy*; D018073:Haemophilus Vaccines / Q000276:immunology / Q000627:therapeutic use; D006193:Haemophilus influenzae / Q000737:chemistry / Q000145:classification / Q000235:genetics / Q000302:isolation & purification / Q000472:pathogenicity*; D006801:Humans; D008581:Meningitis / Q000188:drug therapy / Q000382:microbiology; D011135:Polysaccharides, Bacterial / Q000276:immunology / Q000627:therapeutic use; D012703:Serotyping; D018074:Vaccines, Conjugate; D014774:Virulence
chemical_list: D002511:Cephalosporins; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D019980:Amoxicillin-Potassium Clavulanate Combination